Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena?

Authors Ajoy Kumar, Vibhuti Singh

Published 30 July 2010 Volume 2010:6 Pages 665—669

DOI https://dx.doi.org/10.2147/VHRM.S5686

Review by Single-blind

Peer reviewer comments 2

Ajoy Kumar1, Vibhuti Singh2

1Bayfront Family Medicine Residency, St Petersburg FL, USA; 2University of South Florida College of Medicine and Suncoast Cardiovascular Center, St Petersburg, FL, USA

Abstract: When compared with the general population, the diabetic population is at higher risk of cardiovascular disease (CVD), as predicted by the Framingham Risk Score calculations (10-year risk 20%). For this reason diabetes is considered a “coronary disease equivalent” condition, as classified by the National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III. Furthermore, patients with diabetes who experience a myocar­dial infarction have a poorer prognosis than non­diabetic patients, which contributes to their overall higher mortality. Dyslipidemia is a major underlying risk factor contributing to the excess CVD risk, and is usually more atherogenic in the presence of diabetes. It is uniquely manifested by raised levels of triglycer­ides, low levels of high-density lipoprotein cholesterol, and smaller, denser, and more atherogenic low-density lipoprotein particles. Recent trials have suggested the need for more aggressive treatment of dyslipidemia in this subpopulation than the current recommendations by the NCEP-ATP III. This review addresses the newer developments in the diabetes arena in terms of our current understanding of atherogenic dyslipidemia in diabetes and data from the latest randomized trials addressing its management.

Keywords: atherogenic dyslipidemia, diabetes mellitus

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Low high-density lipoprotein cholesterol: current status and future strategies for management

Vibhuti Singh, Rakesh Sharma, Ajoy Kumar, et al

Vascular Health and Risk Management 2010, 6:979-996

Published Date: 29 October 2010

Argatroban in the management of heparin-induced thrombocytopenia

Luciano Babuin, Vittorio Pengo

Vascular Health and Risk Management 2010, 6:813-819

Published Date: 1 September 2010

Effectiveness of percutaneous laser revascularization therapy for refractory angina

Michael McGillion, Allison Cook, J Charles Victor, et al

Vascular Health and Risk Management 2010, 6:735-747

Published Date: 26 August 2010

Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction

Elmir Omerovic, Truls Råmunddal, Per Albertsson, et al

Vascular Health and Risk Management 2010, 6:657-663

Published Date: 26 August 2010

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

Curtis Triplitt, Eugenio Cersosimo, Ralph A DeFronzo

Vascular Health and Risk Management 2010, 6:671-690

Published Date: 5 August 2010

Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics

Mabrouka El Oudi, Zied Aouni, Haroun Ouertani, et al

Vascular Health and Risk Management 2010, 6:327-332

Published Date: 13 May 2010

Prevalence and risk factors of microalbuminuria in Thai nondiabetic hypertensive patients

Pongsathorn Gojaseni, Angkana Phaopha, Worawon Chailimpamontree, et al

Vascular Health and Risk Management 2010, 6:157-165

Published Date: 11 March 2010

On the antiatherogenic effects of vitamin E: the search for the Holy Grail

Francesco Galli, Dimitrios Kirmizis, Dimitrios Chatzidimitriou

Vascular Health and Risk Management 2010, 6:69-71

Published Date: 16 February 2010

Role of ICAM-1 and E-selectin gene polymorphisms in pathogenesis of PAOD in Egyptian patients

Olfat Shaker, Amr Zahra, Ahmed Sayed, et al

Vascular Health and Risk Management 2010, 6:9-15

Published Date: 24 December 2009